Peanut Allergy Treatment Market Trends

• Epicutaneous immunotherapy is an emerging treatment option for peanut allergies, specifically among pediatric patients. Products such as Viaskin peanut patch has shown promising potential in desensitizing many peanut-allergic pediatric patients. This desensitization helps in lowering the risk of allergic reactions from accidental exposure to peanut. Vendors are increasingly exploring potentials of epicutaneous immunotherapy which is expected to offer lucrative growth opportunities during the forecast period.
  
• Moreover, increasing investments by vendors have resulted in the existence of robust pipeline of potential candidates of immunotherapy drugs such as ADP101, PVX108, VE416, INP20. Owing to their high potential of success, these products are securing significant investments for clinical developments. For instance, in December 2022, Aravax Pty Ltd initiated its series B funding round, through securing an investment of ~USD 22 million to commence phase II clinical trials for PVX108, a promising candidate for treating peanut allergies.